

COST SAVING STUDY OF FIVE GRASS POLLEN SLIT TABLET VERSUS SCIT's & SYMPTOMATIC TREATMENT

Tatar M.¹, Senturk A.², Tuna E.², Darrigol S.³, Girard L.³, Kayin İ.⁴,

¹Hacettepe Universtiy, Ankara, Turkey, ²PolarSağlık Health Economics& Policy, Ankara, Turkey; ³Stallergenes, France, ⁴Stallergenes, Istanbul, Turkey

INTRODUCTION

Allergic rhinitis (AR) is a chronic disease of the upper respiratory tract caused by exposure to allergens inducing inflammation of the nasal mucosa and of the conjunctiva mediated by antibody Immunoglobulin E (IgE).

According to local literature, prevalence of symptomatic AR is around 20% and grass pollen is the most common allergen causing AR in Turkey. 5% of these patients suffer from moderate and severe AR still remain uncontrolled despite symptomatic treatment (Cingi, C et al, (2010), 'Prevalence of allergic rhinitis among the adult population in Turkey', *Acta Oto-Laryngologica*, 130: 600–606.) , Ait-Khaled, N et al, (2009), 'Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three', *Allergy*, 64. 123-148.

Allergen-specific immunotherapy (AIT) is recommended as a second line treatment for patients with moderate to severe allergic rhinitis not or poorly controlled by symptomatic treatments.

The Five Grass Pollen Sublingual Tablet (5GPST) is an alternative AIT in Turkey.

OBJECTIVE

The aim of this budget impact model (BIM) was to assess the cost saving potential of the 5GPST in the Turkish reimbursement system.

METHODOLOGY

Cost calculations were made from the payer perspective as per the guidelines of the Social Security Institution (SSI).

The time horizon considered in the model was one year.

Only direct medical costs were included.

INPUTS OF THE MODEL

Pricing and reimbursement prices data are obtained from Ministry of Health Drug Price List and the Price List of SSI Health Implementation Guideline

The clinical data and Rescue Medication Scores were obtained from published clinical studies. (J. Frew et al. (2006), "Efficacy and Safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis", and (Oralair Phase III clinical trail V061.08 USA, 2012)

Table 1. Immunotherapy costs

Product	Annual number of packs	Annual cost (TL)
Alutard	3	709,10
Allergovit	4	1.892,43
Apsi-Phostal	4	416,75
Novo-Helisen	3	1.138,20
ALK Specific	3	946,28
Oralair(41% discount)	3	597,51

Table 2. AR treatment for a patient treated with symptomatic treatment alone

Product	Unit Cost (TL)	Annual Usage	Total Cost (TL)
Antihistamines	142	1	142
Nasal steroids	84	1	84
Outpatient pack price	31	4	124
Skin prick test	6	1	6
Specific IgE	17	1	17
Total			373

Table 3. AR treatment for a patients treated with SCIT

	Unit Cost (TL)	Annual Usage	Total Cost (TL)
SCIT	1.021	1	1.021
Antihistamines	97	1	97
Nasal steroids	57	1	57
Outpatient pack price	41	10	410
Skin prick test	6	1	6
Specific IgE	17	1	17
Total			1.607

Table 4. AR treatment for a patients treated with SLIT

With %11 discount	Unit Cost (TL)	Annual Usage	Total Cost (TL)
Five Grass Pollen	901	1	901
Antihistamines	76	1	76
Nasal steroids	45	1	45
Outpatient pack price	41	3	123
Skin prick test	6	1	6
Specific IgE	17	1	17
Total			1.168

Table 5. AR treatment for a patients treated with SLIT

With %41 discount	Unit Cost (TL)	Annual Usage	Total Cost (TL)
Five Grass Pollen	598	1	598
Antihistamines	76	1	76
Nasal steroids	45	1	45
Outpatient pack price	41	3	123
Skin prick test	6	1	6
Specific IgE	17	1	17
Total			864

RESULTS

Total cost of AR treatment for a patient treated with symptomatic treatment alone was 373 TL per year and reached to 1.607 TL per year for patients receiving subcutaneous immunotherapy.

Annual total cost of AR per patient with 5GPST with %11 discount for the first reimbursement year is 1.168 TL. Total yearly cost of AR with 5GPST with % 41 discount is 864 TL.

CONCLUSION

In Turkey, compared to subcutaneous AIT, 5GPST is a cost saving alternative for treatment of patients with moderate to severe seasonal AR uncontrolled or not properly controlled by symptomatic treatments, from the SSI perspective.

The treatment is 27% or 46% cheaper with 5GPST with 11% or 41% discount rates respectively.

This study was sponsored by Stallergenes